Labiotech.eu

News and Trends 6 Oct 2015

An Insider’s experience at the iGEM Giant Boston Jamboree 2015

Last week, our Guest blogger Matthieu de Costa (LinkedIn here) attended the iGEM Giant Jamboree at the Hynes Convention Center in Boston (MA). As part of the IONIS iGEM Team from the Sup’Biotech Institute for Biotechnology in Paris (France), his team came back with a Gold medal for their Bio-console video game which aims to […]

October 6, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Medicine Nobel Prize for Parasite Drug Discoveries which saved Billions

The Nobel Prize for Medicine and Physiology has been jointly awarded to Youyou Tu (the first ever Chinese recipient of a Nobel Prize in this category) for discovering the malarial medicine Artemisinin, and to William C. Campbell and Satoshi Ōmura, for their pioneering work in developing a major parasitic round worm disease drug, Ivermectin. These […]

October 5, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

iGEM 2015: Europe still dominates World’s Largest Synthetic Biology Contest

The iGEM 2015 results are out! The World’s largest synthetic biology competition (24th – 28th September) held in Boston (US) has yet again shown up a great European representation in the winning teams. Divided into 3 tiers (Post-graduate, Under-graduate and High-School) winners and their projects are listed below. Originally launched by Massachusetts Institute for Technology […]

October 5, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

€31M goes to a 15-month old Start-up tackling the leading cause of Dwarfism

TherAchon is a 15-month old start-up from the Nice area (France) which has attracted some serious US investors as of late, drawn by their pioneering protein therapy for Achondroplasia (the leading cause of Dwarfism). OrbiMed have now joined New Enterprise Associates and Versant Ventures in a €31 million series A pot for their pre-clinical candidate. […]

October 5, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 3 Oct 2015

What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes

Monday: AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping) Tuesday: Will Roche lose it’s Worldwide Leading position in Cancer treatments? Wednesday: CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9? Thursday: Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government Friday: Merck relinquishes Rare Disease license to instead […]

October 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 2 Oct 2015

Algaemy Fashion: Use of microalgae by Berlin textile design Duo

Berlin-based designers have discovered the aesthetic appeal of manipulating microalgae to produce inks for textile printing. Inspired by work in the German biotech industry, the designer duo was recently subject of a Ted talk praising their creative efforts in founding Algaemy. After visiting the Fraunhofer Institute for Interfacial Engineering and Biotechnology in Munich, Rasa Weber […]

October 2, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Oct 2015

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Merck has opted to return its Phenylketonuria (PKU) candidates Kuvan and Peg-Pal back to BioMarin from January 2016. Merck will instead focus on other R&D areas, and will receive €340M in compensation (5 times the annual sales of Kuvan) with €180M for future Peg-Pal milestones. This appears to support the back-peddling trend of major Biotechs […]

October 2, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Oct 2015

BBSRC: Profile of a UK Biosciences Research Council

A brief profile of The Biotechnology and Biological Sciences Research Council (BBSRC). The BBSRC is the largest UK research council for non-medical biosciences, looking to dominate market in promoting public dialogue on bioscience and funding curiosity-led research, through a direct investment in bioscience research in UK universities and institutes. In particular BBSRC is aiming at promoting […]

October 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 Oct 2015

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

As it’s a new month, we thought we would try something a little different on Labiotech.eu. Every week we are going to showcase a company of our choice found on our map. The goal is to keep everybody up to date on all the various biotech and pharma companies that are found throughout Europe. This week […]

October 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Oct 2015

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

The “Berg Interrogative Biology” program from Boston (US) is a form of artificial intelligence the UK government has employed to work its Genome project. The platform will use a combination of systems biology techniques to analyse up to 100,000 genomes sourced from England’s National Health Service (NHS) for Genomics England (owned by the UK Department […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

An Insider’s experience at the iGEM Giant Boston Jamboree 2015

Medicine Nobel Prize for Parasite Drug Discoveries which saved Billions

iGEM 2015: Europe still dominates World’s Largest Synthetic Biology Contest

€31M goes to a 15-month old Start-up tackling the leading cause of Dwarfism

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes

Algaemy Fashion: Use of microalgae by Berlin textile design Duo

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

BBSRC: Profile of a UK Biosciences Research Council

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!